Drawing for VYDAPTIV

USPTO serial 88664224

VYDAPTIV

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
PARK, JENNY K
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VYDAPTIV?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monica Riva Talley

Monica Riva Talley STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.1100 NEW YORK AVENUE, N.W.WASHINGTON, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Therapeutic protein molecules used in the manufacture of pharmaceutics and biologically-derived medical preparations; all the foregoing to exclude such molecules relating to antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseasesACTIVE—
005Pharmaceutical preparations containing polypeptides, antibodies, or antibody derivatives for the treatment and prophylaxis of cancer and immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseasesACTIVE—
042Research and development in the pharmaceutical and biotechnology fields relating to polypeptides, antibodies or antibody derivatives, in relation to the treatment and prophylaxis of cancer, immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude research and development in relation to antibiotics and the treatment and prophylaxis of infectious diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 30, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 29, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 8, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 7, 2022EX5GSOU EXTENSION 5 GRANTED—
Nov 7, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 28, 2022EXT5SOU EXTENSION 5 FILED—
Oct 28, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 30, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 28, 2022EX4GSOU EXTENSION 4 GRANTED—
Apr 28, 2022EXT4SOU EXTENSION 4 FILED—
Apr 28, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 30, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 28, 2021EX3GSOU EXTENSION 3 GRANTED—
Oct 28, 2021EXT3SOU EXTENSION 3 FILED—
Oct 28, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 30, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 28, 2021EX2GSOU EXTENSION 2 GRANTED—
Apr 28, 2021EXT2SOU EXTENSION 2 FILED—
Apr 28, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 28, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2020EX1GSOU EXTENSION 1 GRANTED—
Oct 26, 2020EXT1SOU EXTENSION 1 FILED—
Oct 26, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 28, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 3, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 3, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 12, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 28, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 28, 2020DOCKASSIGNED TO EXAMINER—
Oct 28, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 25, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance